Company: SXTPW
Filing Date: 2025-06-06
Form Type: DRS
Source: 0001213900-25-052232
Chunk: 29

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-06-06
Form: DRS
Chunk 29
---

Pharmaceuticals, Inc., pursuant to which 60P LLC merged into 60 Degrees Pharmaceuticals, Inc. The value of each outstanding member’s
membership interest in 60P LLC was correspondingly converted into common stock of 60 Degrees Pharmaceuticals, Inc., par value $0.0001
per share, with a cost-basis equal to $300.00 per share.

Our majority-owned subsidiary, 60P Australia Pty
Ltd, an Australian proprietary company limited by shares (“60P Australia”), was formed and registered in Queensland on December
3, 2013, and conducts operations in Australia.

60P Australia previously solely owned a Singaporean
subsidiary company, 60P Singapore Pte. Ltd., which dissolved at our election in the second quarter of 2022.

On February 24, 2025, we effected a reverse stock split of our common
stock at a ratio of 1-for-5.

Going Concern

Our independent auditors have issued a report
raising substantial doubt of our ability to continue as a going concern. We anticipate that we will require additional capital to continue
as a going concern and expand our operations in accordance with our current business plan.

Suppliers

We have quality and contract manufacturing agreements
relating to Arakoda in place with Piramal Enterprises Limited (API, tablets) and PCI Pharma Services (secondary packaging) (“PCI”)
and supply/quality/pharmacovigilance agreements in place with Biocelect Pty Ltd, Scandinavian Biopharma, and Knight Therapeutics Inc.
(to allow supply of Arakoda/Kodatef to Australia, Europe and Canada/Israel/Latin America and Russia, respectively). As of the date of
this prospectus, we have not supplied any of our products to Russia nor do we anticipate supplying any of our products to Russia in the
near future.

Recent Developments

New FSU Option Agreement

On April 4, 2025, we entered into an option agreement
(the “Option Agreement”) with FSURF, the owner of certain patent rights and other patent and technology rights (“Patent
and Technology Rights”) relating to large scale purification of castanospermine.

Pursuant to the Option Agreement, FSURF granted
us an exclusive, limited-term option to negotiate a royalty-bearing, exclusive license to such Patent and Technology Rights within defined
fields of use (the “Option Rights”).

The option period commenced on April 4, 2025,
and will continue for